Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 137

1.

Early results of prostate cancer radiation therapy: an analysis with emphasis on research strategies to improve treatment delivery and outcomes.

Yamoah K, Beecham K, Hegarty SE, Hyslop T, Showalter T, Yarney J.

BMC Cancer. 2013 Jan 16;13:23. doi: 10.1186/1471-2407-13-23.

PMID:
23324165
[PubMed - indexed for MEDLINE]
Free PMC Article
2.

Impact of race on biochemical disease recurrence after prostate brachytherapy.

Yamoah K, Stone N, Stock R.

Cancer. 2011 Dec 15;117(24):5589-600. doi: 10.1002/cncr.26183. Epub 2011 Jun 20.

PMID:
21692058
[PubMed - indexed for MEDLINE]
Free Article
3.

What pretreatment prostate-specific antigen level warrants long-term androgen deprivation?

Feigenberg SJ, Hanlon AL, Horwitz EM, Uzzo RG, Eisenberg DF, Pollack A.

Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1003-10.

PMID:
15752879
[PubMed - indexed for MEDLINE]
4.

Biochemical outcomes after prostate brachytherapy with 5-year minimal follow-up: importance of patient selection and implant quality.

Kollmeier MA, Stock RG, Stone N.

Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):645-53.

PMID:
14529768
[PubMed - indexed for MEDLINE]
5.

PSA nadir of <0.5 ng/mL following brachytherapy for early-stage prostate adenocarcinoma is associated with freedom from prostate-specific antigen failure.

Ko EC, Stone NN, Stock RG.

Int J Radiat Oncol Biol Phys. 2012 Jun 1;83(2):600-7. doi: 10.1016/j.ijrobp.2011.07.009. Epub 2011 Oct 8.

PMID:
21985944
[PubMed - indexed for MEDLINE]
6.

Dose-escalated radiotherapy for high-risk prostate cancer: outcomes in modern era with short-term androgen deprivation therapy.

Liauw SL, Stadler WM, Correa D, Weichselbaum RR, Jani AB.

Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):125-30. doi: 10.1016/j.ijrobp.2009.04.074. Epub 2009 Aug 19.

PMID:
19695789
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era.

Kupelian PA, Buchsbaum JC, Patel C, Elshaikh M, Reddy CA, Zippe C, Klein EA.

Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):704-11.

PMID:
11849793
[PubMed - indexed for MEDLINE]
8.

Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.

Fitch DL, McGrath S, Martinez AA, Vicini FA, Kestin LL.

Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1430-9. Epub 2006 Jun 12.

PMID:
16765527
[PubMed - indexed for MEDLINE]
9.

Failure-free survival following brachytherapy alone or external beam irradiation alone for T1-2 prostate tumors in 2222 patients: results from a single practice.

Brachman DG, Thomas T, Hilbe J, Beyer DC.

Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):111-7.

PMID:
10924979
[PubMed - indexed for MEDLINE]
10.

Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.

Martinez AA, Demanes DJ, Galalae R, Vargas C, Bertermann H, Rodriguez R, Gustafson G, Altieri G, Gonzalez J.

Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1322-31.

PMID:
16029788
[PubMed - indexed for MEDLINE]
11.

Statin use and risk of prostate cancer recurrence in men treated with radiation therapy.

Gutt R, Tonlaar N, Kunnavakkam R, Karrison T, Weichselbaum RR, Liauw SL.

J Clin Oncol. 2010 Jun 1;28(16):2653-9. doi: 10.1200/JCO.2009.27.3003. Epub 2010 Apr 26.

PMID:
20421534
[PubMed - indexed for MEDLINE]
Free Article
12.

The addition of low-dose-rate brachytherapy and androgen-deprivation therapy decreases biochemical failure and prostate cancer death compared with dose-escalated external-beam radiation therapy for high-risk prostate cancer.

Shilkrut M, Merrick GS, McLaughlin PW, Stenmark MH, Abu-Isa E, Vance SM, Sandler HM, Feng FY, Hamstra DA.

Cancer. 2013 Feb 1;119(3):681-90. doi: 10.1002/cncr.27784. Epub 2012 Aug 14.

PMID:
22893254
[PubMed - indexed for MEDLINE]
Free Article
13.

Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer.

Kupelian PA, Potters L, Khuntia D, Ciezki JP, Reddy CA, Reuther AM, Carlson TP, Klein EA.

Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):25-33.

PMID:
14697417
[PubMed - indexed for MEDLINE]
14.

Factors affecting recurrence rates after prostatectomy or radiotherapy in localized prostate carcinoma patients with biopsy Gleason score 8 or above.

Kupelian PA, Buchsbaum JC, Elshaikh M, Reddy CA, Zippe C, Klein EA.

Cancer. 2002 Dec 1;95(11):2302-7.

PMID:
12436435
[PubMed - indexed for MEDLINE]
Free Article
15.

Higher than standard radiation doses (> or =72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer.

Kupelian PA, Mohan DS, Lyons J, Klein EA, Reddy CA.

Int J Radiat Oncol Biol Phys. 2000 Feb 1;46(3):567-74.

PMID:
10701735
[PubMed - indexed for MEDLINE]
16.

Association of percent positive prostate biopsies and perineural invasion with biochemical outcome after external beam radiotherapy for localized prostate cancer.

Wong WW, Schild SE, Vora SA, Halyard MY.

Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):24-9.

PMID:
15337536
[PubMed - indexed for MEDLINE]
17.

Radical radiotherapy in high-risk prostate cancer patients with high or ultra-high initial PSA levels: a single institution analysis.

Guarneri A, Botticella A, Filippi AR, Ruggieri A, Piva C, Munoz F, Ragona R, Gontero P, Ricardi U.

J Cancer Res Clin Oncol. 2013 Jul;139(7):1141-7. doi: 10.1007/s00432-013-1426-0. Epub 2013 Apr 4.

PMID:
23552872
[PubMed - indexed for MEDLINE]
18.

Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.

Kupelian PA, Katcher J, Levin HS, Klein EA.

Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1043-52.

PMID:
9169811
[PubMed - indexed for MEDLINE]
19.

Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.

Galalae RM, Martinez A, Mate T, Mitchell C, Edmundson G, Nuernberg N, Eulau S, Gustafson G, Gribble M, Kovács G.

Int J Radiat Oncol Biol Phys. 2004 Mar 15;58(4):1048-55.

PMID:
15001244
[PubMed - indexed for MEDLINE]
20.

Improvement in relapse-free survival throughout the PSA era in patients with localized prostate cancer treated with definitive radiotherapy: year of treatment an independent predictor of outcome.

Kupelian PA, Buchsbaum JC, Elshaikh MA, Reddy CA, Klein EA.

Int J Radiat Oncol Biol Phys. 2003 Nov 1;57(3):629-34.

PMID:
14529766
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk